BLAINTRAMUSCULAR, SUBCUTANEOUSINJECTABLE
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
DAXXIFY (botulinum toxin type a) by Cerevance is acetylcholine release inhibitors [moa]. Approved for migraine, muscle spasticity, glabellar lines and 6 more indications. First approved in 2022.
Drug data last refreshed Yesterday
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications (9)
Worked on DAXXIFY at Cerevance? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.